C. Dunstan

发表

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

S. Morony, D. Lacey, I. Sarosi, 1998, Genes & development.

Osteoprotegerin ameliorates sciatic nerve crush induced bone loss

T. Bateman, D. Lacey, V. Ferguson, 2001, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

P. Kostenuik, S. Morony, D. Lacey, 2022 .

Systemic Administration of Acidic Fibroblast Growth Factor (FGF‐1) Prevents Bone Loss and Increases New Bone Formation in Ovariectomized Rats

G. Mundy, B. Boyce, I. Garrett, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis.

P. Kostenuik, S. Morony, D. Lacey, 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

Characterization of osteoclast precursors in human blood

D. Lacey, N. Hawkins, M. Kelley, 2000, British journal of haematology.

The Receptor Activator of Nuclear Factor-κB Ligand Inhibitor Osteoprotegerin Is a Bone-Protective Agent in a Rat Model of Chronic Renal Insufficiency and Hyperparathyroidism

P. Kostenuik, S. Morony, D. Lacey, 2005, Calcified Tissue International.

TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling.

S. Morony, D. Lacey, D. Goeddel, 1999, Genes & development.

A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3.

S. Morony, D. Lacey, T. Boone, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation

D. Lacey, I. Sarosi, J. Delaney, 1998, Cell.

Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density

G Shimamoto, D. Lacey, T. Boone, 1997, Cell.

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.

S. Morony, D. Lacey, M. Bass, 1999, Proceedings of the National Academy of Sciences of the United States of America.

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.

D L Lacey, P. Kostenuik, S. Morony, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.

P. Kostenuik, S. Morony, D. Lacey, 2001, Cancer research.

Osteoprotegerin mitigates tail suspension-induced osteopenia.

T. Bateman, D. Lacey, V. Ferguson, 2000, Bone.